Targeted intraoperative radiotherapy (targit) yields very low recurrence rates when given as a boost
Purpose: Patients undergoing breast-conserving surgery were offered boost radiotherapy with targeted intraoperative radiotherapy (TARGIT) using the Intrabeam system to test the feasibility, safety, and efficacy of the new approach. Methods and Materials: We treated 302 cancers in 301 unselected pati...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2 November 2006
|
| In: |
International journal of radiation oncology, biology, physics
Year: 2006, Volume: 66, Issue: 5, Pages: 1335-1338 |
| ISSN: | 1879-355X |
| DOI: | 10.1016/j.ijrobp.2006.07.1378 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ijrobp.2006.07.1378
|
| Author Notes: | Jayant S. Vaidya, Michael Baum, Jeffrey S. Tobias, Samuele Massarut, Frederik Wenz, Olive Murphy, Basil Hilaris, Joan Houghton, Christobel Saunders, Tammy Corica, Mario Roncadin, Uta Kraus-Tiefenbacher, Frank Melchaert, Mohammed Keshtgar, Richard Sainsbury, Michael Douek, Elly Harrison, Alastair Thompson, David Joseph |
| Summary: | Purpose: Patients undergoing breast-conserving surgery were offered boost radiotherapy with targeted intraoperative radiotherapy (TARGIT) using the Intrabeam system to test the feasibility, safety, and efficacy of the new approach. Methods and Materials: We treated 302 cancers in 301 unselected patients. This was not a low-risk group. One-third of patients (98/301) were younger than 51 years of age. More than half of the tumors (172, 57%) were between 1 cm and 2 cm, and one-fifth (62, 21%) were > 2 cm; 29% (86) had a Grade 3 tumor and, in 29% (87), axillary lymph nodes contained metastasis. After primary surgery, 20 Gy was delivered intraoperatively to the surface of the tumor bed, followed by external-beam radiotherapy (EBRT), but excluding the usual boost. Results: The treatment was well tolerated. The follow-up ranged from 3 to 80 months (164 and 90 patients completed 2 and 3 years follow-up, respectively). Four patients (1.3%) had local recurrence. The Kaplan-Meier estimate of local recurrence is 2.6% (SE = 1.7) at 5 years. This compares favorably with the 4.3% recurrence rate in boosted patients from the EORTC boost study, in which only 8.1% patients were node-positive, as opposed to 29% in our series. Conclusion: Targeted intraoperative radiotherapy combined with EBRT results in a low local recurrence rate. This could be attributed to both accurate targeting and timeliness of the treatment. These data support the need for a randomized trial to test whether the TARGIT boost is superior to conventional external boost, especially in high-risk women. (c) 2006 Elsevier Inc. |
|---|---|
| Item Description: | Gesehen am 24.02.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1879-355X |
| DOI: | 10.1016/j.ijrobp.2006.07.1378 |